Cover Image
市場調查報告書

伊波拉報告:2014年的大流行和研究開發中的治療藥之未來發展預測

The Ebola Report: 2014 Epidemic and R&D Drug Prospects

出版商 Visiongain Ltd 商品編碼 318754
出版日期 內容資訊 英文 115 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
伊波拉報告:2014年的大流行和研究開發中的治療藥之未來發展預測 The Ebola Report: 2014 Epidemic and R&D Drug Prospects
出版日期: 2014年11月14日 內容資訊: 英文 115 Pages
簡介

本報告詳查伊波拉出血熱的診斷,預防,及治療用醫藥品市場,提供您這個市場擁有怎樣方市場機會,還有驗証該市場相關技術之商業性預測如何?同時更提供研究開發中的醫藥品預測與市場上的未來性分析,以及伊波拉診斷用醫藥品,疫苗及治療藥相關的生存競爭,最後更提供這個市場主要企業為何及其評估分析。

第1章 調查報告概要

第2章 伊波拉出血熱序論:起源,歷史,及流行病學的觀察

  • 伊波拉病毒
    • 伊波拉病毒的自我複製機制 -宿主細胞陷入典型的人質狀態
  • 伊波拉病毒病 - 致命的出血性疾病
    • 伊波拉病毒感染症的症狀
    • 伊波拉病毒的疾病感染流程
  • 伊波拉出血熱的流行 - 騷亂的歷史
    • Kikwit1995年的流行-死亡率及因應措施
    • 1995年以後的伊波拉出血熱的流行
  • 伊波拉病毒 - 自然地與店主感染途徑
    • 伊波拉病毒的分子生物學傳染機制
    • 由野生生物傳染給人類
    • 由人類傳染給人類

第3章 2014年的伊波拉出血熱大流行-現狀評估及未來的發生預測

  • 由於人口移動的增加助長了病毒的迅速擴散
    • 非洲以外的伊波拉 - 是否為全球性蔓延的潛在威脅警報?
    • 2014年末伊波拉出血熱的新爆炸性流行 - 為防止病毒擴散,努力的空間為何?
  • Ro(增生率)計算 - 預測伊波拉蔓延率的方法
  • 阻止伊波拉病毒擴散到西非洲的方策
    • 控制伊波拉蔓延的方法之一般大眾的參與計劃
  • 現在實施的伊波拉蔓延封鎖策略的缺點
  • 伊波拉出血熱發生過程與蔓延監視模式的嘗試
  • 未來的伊波拉病毒感染(EVD)的發生預測
  • EVD的發生及流行預測的限制

第4章 伊波拉診斷:現在銷售中以及開發階段的產品分析-2014年

  • 體外診斷用醫藥品(IVD)檢驗是什麼?
  • 體外診斷檢驗的類別
    • 醫療器具方面美國的分類法
    • 醫療器具方面EC (歐洲委員會的)分類法
  • 體外診斷檢驗用醫藥品的使用相關法規
  • 要防止伊波拉迅速蔓延,需要臨床現場即時檢測工具
  • 伊波拉用的體外診斷用醫藥品檢驗
    • 免疫化學的檢驗- 更能明確查出伊波拉病毒的方法
  • 現在所用的伊波拉病毒診斷檢驗
    • ELISA (酵素結合免疫吸著法)
      • ELISA的形式 - 各種檢測方式
  • 伊波拉診斷工具的ELISA
    • 反轉錄聚合酶鍊式反應(RT-PCR)
    • 病毒的分離 - 可靠的伊波拉診斷法
  • 以目前可使用的伊波拉診斷工具為中心課題
  • 處於開發階段的伊波拉診斷用產品
    • Corgenix Medical Corporation - 快速的伊波拉診斷檢測套組

第5章 伊波拉治療藥: 開發階段的醫藥品分析 - 2014年

  • 伊波拉醫藥品: 推動開發的集中努力
  • BioCryst Pharmaceuticals - BCX4430
  • Chimerix Inc - Brincidofovir
  • Leaf BioPharma/ Mapp BioPharma/ Defyrus Inc - ZMapp
  • Serepta Therapeutics - AVI-7537
  • Tekmira Pharmaceuticals - TKM-Ebola
  • 富山化學工業/FUJIFILM Holdings - favipiravir
  • Viiv Healthcare - Lamivudine
  • 恢復期血清

第6章 伊波拉疫苗: 開發階段分析 - 2014年

  • 疫苗是什麼?
  • 日常性的成人疫苗接種是否能在下一個十年中實現?
  • GlaxoSmithKline - ChAd-EBOV疫苗
  • Johnson & Johnson/ Bavarian Nordic - AdVac/MVA-BN技術為基礎的伊波拉疫苗
  • NewLink Genetic Corporation/ PHAC - rVSV疫苗
  • Profectus BioSciences - VesiculoVax
  • 伊波拉疫苗的市場在哪裡,朝何處發展?
    • 將重點置於「滿足必要」之法制影響未來伊波拉疫苗使用法的可能性
    • 妨礙伊波拉治療藥擴大生產的要素

第7章 伊波拉出血熱的經濟及社會政治影響

  • 遭受嚴重流行的三個國家伊波拉出血熱的經濟影響
  • 伊波拉出血熱對全球經濟的影響
  • 對伊波拉醫藥品市場的經濟優點
  • 為了防止伊波拉蔓延美國當局實施的對策
  • 伊波拉出血熱的亞洲流行可能性與預測將發生的社會政治影響
  • 伊波拉這個潛在性生物恐怖行動的威脅

第8章 與伊波拉奮戰的人道努力 - 對抗策略和其效果的相關評估

  • 2014年對伊波拉出血熱的人道支援穩定增加
  • 政府機關和民間組織在支援伊波拉奮戰努力方面的援助
  • 西非洲的伊波拉治療中心的營運成本
  • 西非洲支援伊波拉的其他組織及資金
  • 暴露在伊波拉風險下地區社會照護的實施手法

第9章 基於本公司的重要調查之專家見解

第10章 結論

  • 2014年的伊波拉出血熱大流行概要 - 最大的歷史事實
  • 伊波拉病毒檢測所採用的診斷方法 - 需要可迅速查出的技術
  • 為了對抗伊波拉正在開發的醫藥品 - 以安全性和效力為中心的課題
  • 伊波拉疫苗 - 免疫防禦力可持續到多久?
  • 對抗2014年的伊波拉大流行之人道支援可望發揮多大效果?
  • 西非洲若無伊波拉出血熱,其社會政治情形將會如何不同?

刊載企業一覽

刊載團體組織一覽

目錄
Product Code: PHA0014

The Ebola Report - new study showing you trends and R&D progress

What opportunities are there in a market for Ebola diagnostics, prevention, and treatment? What are the commercial prospects for this market and related technologies? Visiongain's new report shows market potential for products and other trends, discussing data, opportunities and prospects.

Our new 115 page report provides 40 tables, charts, and graphs. Discover the R&D prospects of products in the pipeline and their future market potential. Our new study lets you assess the leading candidates in the race for entry into the market for Ebola diagnostics, vaccines, and treatments. You will see interviews, trends, and opportunities that may arise.

Future outlook and other analyses show you commercial prospects

Our new study provides you with original analyses, with business outlooks and developments. Discover qualitative analyses, product profiles and commercial developments. Read the full transcripts of two exclusive expert opinion interviews from industry specialists informing your understanding and allowing you to assess prospects for investments and sales:

  • Prof. Sunetra Gupta, Professor of Theoretical Epidemiology, University of Oxford
  • Dr Derek Gatherer, Division of Biomedical and Life Sciences, Lancaster University

You find prospects for the R&D pipeline of key submarkets

What is happening in the R&D pipeline for Ebola diagnostics, drugs and vaccines? You see developmental trends, gaining insight into the current products in development. In addition to analyses of currently used Ebola pharma/Medtech products, you see analyses for the pipeline of these three product categories:

  • Ebola diagnostics
  • Ebola treatments
  • Ebola vaccines

Drugs that can significantly reduce the high mortality rate associated with infections with the Ebola virus whilst reducing the many grievous symptoms will achieve success. Vaccines aimed at protecting front-line healthcare workers treating patients infected with the Ebola virus will prove successful and financially viable to developers and manufacturers

Our investigation shows business research and analyses with individual product evaluations and discussions. You find the dynamics of the industry and assess its potential growth, seeing agents likely to achieve the most success.

See insightful analysis for products

What are the characteristics of the most promising drugs and vaccines being developed or tested to treat or prevent Ebola? How will promising products currently in the pipeline perform once they are launched? Our study profiles promising Ebola drugs including these:

  • ZMapp
  • Brincidofivir
  • BCX4430
  • AVI-7537
  • Lamivudine
  • Favipiravir
  • TKM-Ebola

You will see what is happening, understanding trends, challenges and opportunities. Discover features and profiles for Ebola vaccines currently under development. These include:

  • VesiculoVax
  • GSK's ChAd vaccine
  • New Link Genetic Corp's rVSV vaccine
  • Johnson & Johnson/ Bavarian Nordic AdVac/ MVA-BN Technology-based vaccine

What are the prospects for the various regions and countries?

Which countries are most at risk? Which countries are best prepared to tackle potential cases of Ebola? Regulatory approvals and the trends being observed for some products getting fast tracked will play a crucial role in shaping the future of the market for Ebola drugs and vaccines. Our analyses show a rapid uptake for products targeting the Ebola virus and Ebola virus disease on the back of the devastation caused by the Ebola virus disease outbreak in West Africa in 2014. In particular, the countries in North America and Europe will look to stock up on Ebola drugs and vaccines to counter the risk of Ebola virus disease spreading into the region. Furthermore, the potential threat of the Ebola virus being used as a possible bio-terror agent will also influence the uptake and launch of new drugs.

Regulatory, demographic, and commercial developments worldwide will influence the markets both in the established North American and Western European economies, and the fast-rising emerging markets.

Discover R&D efforts from leading pharmaceutical companies

Rising demand for safe and effective Ebola drugs and diagnostics, increasing healthcare coverage, increased commitment to product testing and a strong R&D pipeline will expand the market for these products in the near future.

Our work shows you products from various organisations that hold great potential for diagnosing, preventing, and treating Ebola. These organisations include:

  • BioCryst Pharmaceuticals
  • Chimerix Inc
  • GlaxoSmithKline
  • Johnson & Johnson
  • Mapp BioPharma
  • New Link Genetic Corporation
  • Profectus BioSciences
  • Serepta Therapeutics
  • Tekmira Pharmaceuticals

You gain the following information:

  • Discussions of a company's activities, including product portfolios and pipeline drugs focused on the treatment and prevention of Ebola
  • Assessment of recent developments relating to Ebola - mergers and acquisitions (M&A), new products, and collaborations, including alliances, partnerships and joint ventures.

Discover capabilities, progress, and commercial prospects, helping you stay ahead.

What issues will affect the market for Ebola diagnostics, drugs, and vaccines?

Our new report discusses issues and events affecting Ebola-related pharmaceutical and medical technology products. This includes the major impact that the outbreak of the virus in 2014 has had on preparedness levels in various regions globally. You will find discussions of many issues and developments, including:

  • Mode of transmission for Ebola virus and the changing pattern of spread witnessed in the 2014 outbreak
  • Regulatory approval as a hindrance to product launch
  • Evaluation of containment strategies being used to curb the spread of Ebola during the 2014 outbreak of the disease
  • Examination of currently-used diagnostic methods for Ebola and the developments being implemented to improve these methods
  • Understanding the sources of funding for the development of Ebola drugs and vaccines
  • Safety and patient compliance
  • Clinical evidence supporting product efficacy

Our investigation gives you multi-level business research and analyses. You see how that industry will grow over the coming years.

How The Ebola Report: 2014 Epidemic And R&D Drug Prospects helps you

In summary our 115 page report gives you the following knowledge:

  • Outlook for the overall Ebola pharmaceutical and medical technology market and 3 submarkets - discover the industry's prospects, finding promising areas for investments and revenues
  • Profiles and analyses of 8 products currently being tested as Ebola treatments - discover prospects for promising therapies in the pipeline
  • Evaluation of 4 pipeline Ebola vaccines - find the market potential for leading vaccine products currently in the development pipeline
  • Assessment of the humanitarian response to the 2014 Ebola outbreak in West Africa - hear about relief efforts from the international community and non-government organisations, and the effects of these on the spread of Ebola.
  • The socio-economic impact of Ebola - get an insight into the effect the 2014 Ebola outbreak had on West Africa's productivity and the wider economic impact on other regions globally
  • Discussion of what stimulates and restrains companies and the market
  • Prospects for firms currently developing products and those seeking to enter the market
  • Opinions from our survey, seeing interviews with industry authorities

You will find quantitative and qualitative analyses with independent predictions. You receive information that only our report contains, staying informed with this invaluable business intelligence.

Information found nowhere else

With our survey you are less likely to fall behind in knowledge or miss opportunities. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight.

Visiongain's study is for everybody needing commercial analyses for Ebola diagnostics, drugs, and vaccines. You will find data, trends and predictions. Please order our report now.

Visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Report Overview

  • 1.1. Ebola Virus And Ebola Virus Disease: An Overview
  • 1.2. Ebola Diagnostic Tools And The Global Pipeline For Ebola Vaccines And Treatments
  • 1.3. Why You Should Read This Report
  • 1.4. How This Report Delivers
  • 1.5. Key Questions Answered By This Analytical Report
  • 1.6. Who Is This Report For?
  • 1.7. Methodology
  • 1.8. Associated Reports
  • 1.9. About Visiongain

2. An Introduction To Ebola: Origin, History, and Epidemiology

  • 2.1. The Ebola Virus
    • 2.1.1. Ebola Virus Replication Mechanism - Host Cell Typically Held Hostage
  • 2.2. Ebola Virus Disease - A Lethal Haemorrhagic Disease
    • 2.2.1. Symptoms of Ebola Virus Disease
    • 2.2.2. Progression Over Time From Infection By Ebola Virus
  • 2.3. Ebola Outbreaks - A Tumultuous History
    • 2.3.1. Kikwit Ebola Outbreak Of 1995 - Mortality And Response
    • 2.3.2. Post-1995 Outbreaks Of Ebola
  • 2.4. Ebola Virus - Natural Reservoir And Mode Of Transmission
    • 2.4.1. Molecular Mechanism of Ebolavirus Transmission
    • 2.4.2. Wild-Life To Human Transmission
    • 2.4.3. Human To Human Transmission

3. Ebola Outbreak Of 2014: Current Assessment and Projections for Future Incidence

  • 3.1. Rapid Spread Of The Virus Aided By Rising Migration
    • 3.1.1. Ebola Outside Of Africa - Does This Signal Possibility Of Global Spread?
    • 3.1.2. Explosion Of New Ebola Cases In Late 2014 - Where Does This Leave Efforts To Curb The Spread Of The Virus?
  • 3.2. Ro Calculations - A Method Of Predicting The Rate Of Ebola Spread
  • 3.3. Containment Measures For Ebola Virus Spread In West Africa
    • 3.3.1. Public Engagement As A Way Of Containing Ebola Spread
  • 3.4. Downsides To The Strategies Currently In Place To Contain The Spread Of Ebola
  • 3.5. Efforts To Monitor Incidence Flow And The Pattern Of Spread
  • 3.6. Projections For Future Incidence Of Ebola Virus Disease (EVD)
  • 3.7. Limitations To Forecasting EVD Incidence And Spread

4. Ebola Diagnostics: Currently Marketed Products And Pipeline Analysis, 2014

  • 4.1. What are In Vitro Diagnostic (IVD) Tests?
  • 4.2. Classifying In Vitro Diagnostics
    • 4.2.1. The US Classification For Medical Devices
    • 4.2.2. The EC (European Commission) Classification For Medical Devices
  • 4.3. Regulations Surrounding The Use Of IVD Tests
  • 4.4. Point Of Care Diagnostics Tools Are Necessary For Swift Ebola Containment
  • 4.5. In Vitro Diagnostic Tests For Ebola
    • 4.5.1. Immunochemistry - A Clearer Means Of Detecting Ebola Virus
  • 4.6. Currently Used Diagnostic Tests For Ebola Virus
    • 4.6.1. Enzyme-linked Immunosorbent Assay (ELISA)
      • 4.6.1.1. ELISA Formats - Varying Modes Of Detection
  • 4.6.1.2. ELISA As A Tool For Ebola Diagnosis
    • 4.6.2. Reverse Transcription Polymerase Chain Reaction (RT-PCR)
    • 4.6.3. Virus Isolation - Reliable Method Of Diagnosing Ebola
  • 4.7. Issues Around The Currently Available Ebola Diagnostic Tools
  • 4.8. Diagnostic Products In The Pipeline For Ebola
    • 4.8.1. Corgenix Medical Corporation - Rapid Ebola Diagnostic Test Kit

5. Ebola Treatments: Pipeline Analysis, 2014

  • 5.1. Ebola Drugs: Intensifying Efforts In Development Drive
  • 5.2. BioCryst Pharmaceuticals - BCX4430
  • 5.3. Chimerix Inc - Brincidofovir
  • 5.4. Leaf BioPharma/ Mapp BioPharma/ Defyrus Inc - ZMapp
    • 5.4.1. Development Efforts For ZMapp
  • 5.5. Serepta Therapeutics - AVI-7537
    • 5.5.1. Development Efforts For AVI-7537 & AVI-6002
  • 5.6. Tekmira Pharmaceuticals - TKM-Ebola
    • 5.6.1. Development Efforts For TKM-Ebola
    • 5.6.2. Progress Of Clinical Trials For TKM-Ebola
    • 5.6.3. Increasing TKM-Ebola Manufacturing Signals Positive Outlook For The Therapy
  • 5.7. Toyama Chemical Co Ltd/ Fujifilm Holding Corp - Favipiravir
  • 5.8. Viiv Healthcare - Lamivudine
  • 5.9. Convalescent Serum

6. Ebola Vaccines: Pipeline Analysis, 2014

  • 6.1. What Are Vaccines?
    • 6.1.1. Paediatric Vaccines
    • 6.1.2. Adult Prophylactic Vaccines
  • 6.2. Will Routine Adult Vaccination Become A Reality Over The Next Decade?
    • 6.2.1. Extensive Pipeline, But Adult Immunisation Still Needs to Become More Widely Established
  • 6.3. GlaxoSmithKline - ChAd-EBOV Vaccine
    • 6.3.1. Development Efforts For GSK/NIAID's Ebola Vaccine
    • 6.3.2. Future Plans For The Development Of GSK's Vaccine
    • 6.3.3. Issues With The GSK/NIAID Ebola Vaccine
  • 6.4. Johnson & Johnson/ Bavarian Nordic - AdVac/MVA-BN Technology-Based Ebola Vaccine
    • 6.4.1. Development Efforts For J&J/Bavarian Nordic's Ebola Vaccine
    • 6.4.2. Johnson & Johnson's Humanitarian Efforts During The 2014 Ebola Outbreak
  • 6.5. NewLink Genetic Corporation/ PHAC - rVSV Vaccine
  • 6.6. Profectus BioSciences - VesiculoVax
    • 6.6.1. Development Efforts For VesiculoVax
    • 6.6.2. Funding Flowing In For Development Of VesiculoVax
  • 6.7. Where Does The Market For Ebola Vaccines Stand And Where Is It Going?
    • 6.7.1. Regulations Around ‘Fill Capacity' May Impact Future Use Of Ebola Vaccines
    • 6.7.2. Factors That May Hinder Scaling Up Production Of Ebola Treatments

7. Economic And Socio-Political Impacts Of Ebola

  • 7.1. The Economic Impact Of Ebola On The Three Worst-Hit Nations
    • 7.1.1. Crippling Domestic Food Production Leading To Inflation
    • 7.1.2. Impact Of The Ebola Outbreak On Manufacturing, Natural Resources, And Other Service Sectors
    • 7.1.3. The Economic Impact Of The 2014 Ebola Outbreak On West Africa
    • 7.1.4. Lax Border Control Contributing To The Spread Of Ebola
  • 7.2. The Global Economic Impacts Of Ebola
  • 7.3. The Economic Benefits Of An Ebola Drugs Market
  • 7.4. Measures Being Implemented By US Authorities For Preventing The Spread Of Ebola
  • 7.5. The Potential Spread Of Ebola In Asia And The Likely Socio-Economic Impacts
    • 7.5.1. Evaluation Of India's Preparedness For An Ebola Outbreak
    • 7.5.2. China - How Prepared Is The World's Most Populous Nation To Deal With Ebola
    • 7.5.3. Japan Being Urged To Increase Its Response To The Fight Against Ebola
  • 7.6. Ebola As A Potential Bioterrorism Threat
    • 7.6.1. Criteria Used For Categorising Bio-terror Threats
    • 7.6.2. Major Bio-terror/Bio-warfare Threats
      • 7.6.2.1. Anthrax (Bacillus anthracis)
      • 7.6.2.2. Botulism (Clostridium botulinum toxin)
      • 7.6.2.3. Bubonic Plague (Yersinia pestis)
      • 7.6.2.4. Ricin (Ricinus communis)
      • 7.6.2.5. Smallpox (Variola major)
      • 7.6.2.6. Tularaemia (Francisella tularensis)
      • 7.6.2.7. Viral hemorrhagic Fevers - Ebola And Marburg Viruses
    • 7.6.3. Bio-terrorism Preparedness
    • 7.6.4. The Future Of Ebola As A Biodefense Threat

8. Humanitarian Efforts To Combat Ebola - Evaluation Of Response And Its Effectiveness

  • 8.1. A Steady Increase In Humanitarian Relief For Ebola Over 2014
  • 8.2. Governmental- And Non-Governmental Organisations Aiding In The Relief Effort To Combat Ebola
  • 8.3. The Cost Of Running Ebola Treatment Centres In West Africa
  • 8.4. Other Organisations And Their Pledges To The Ebola Relief Efforts In West Africa
  • 8.5. Measures Being Implemented For Care In The Communities Affected By Ebola

9. Expert Opinions from Our Primary Research

  • 9.1. Interview With Dr Derek Gatherer, Division Of Biomedical And Life Sciences At Lancaster University, UK.
    • 9.1.1. Issues Around The Use Of Convalescent Blood Transfusion As A Treatment For EVD
    • 9.1.2. An Evaluation Of ZMapp As A Drug For EVD
    • 9.1.3. How Far Away Are Small Drug Molecules Being Developed From Entering The Market
      • 9.1.3.1. Favipiravir And Cidofovir As Possible Treatments For EVD
      • 9.1.3.2. Does BCX-4460's Effectiveness In Non-Human Primates Translate To Possible Market Potential
    • 9.1.4. The Trade-Off Between Modern Drug Design Technologies And Animal Models For Developing Drugs
    • 9.1.5. On The Role That Viral Surface Proteins Play In The Development Of Vaccines Targeted At The Virus
    • 9.1.6. Clinical Trials Planned For Ebola Vaccine In 2014/15 And The Logistical Plans Being Implemented
    • 9.1.7. Ebola Preparedness: Assessments And other Processes Being Implemented To Prevent The Dissemination Of Ebola Virus
    • 9.1.8. On How The Study Of Viral Phylogenetics Will Impact The Design Of Ebola Vaccines And Therapies
    • 9.1.9. Is The Slowing Rate Of EVD Spread A Reliable Indicator Of The Ebola Outbreak Subsiding
    • 9.1.10. The Southeastward Spread Of EVD In West Africa And The Implications For Countries In The Region
  • 9.2. Interview With Professor Sunetra Gupta, Professor Of Theoretical Epidemiology, University Of Oxford, UK
    • 9.2.1. Should We Worry More About Influenza Viruses Than We've Worried About Ebola
    • 9.2.2. Global Connectedness - A Factor Increasing The Risk Of Ebola Spread?
    • 9.2.3. Issues With Safety And Immunogenicity Tests For Vaccines Currently Being Developed
    • 9.2.4. The Genomic Revolution - How New Information Streams Are Opening Doors To Novel Vaccine Designs
    • 9.2.5. The Future Outlook For Development Of Vaccines Against Virus Such As Ebola

10. Conclusions

  • 10.1. Overview Of The 2014 Ebola Outbreak - The Largest In History
  • 10.2. Diagnostic Methods Used In Detecting Ebola Virus - More Rapid Technologies Needed
  • 10.3. Drugs Being Developed To Combat Ebola - Issues Around Safety And Efficacy
  • 10.4. Ebola Vaccines - For How Long Will The Protection Last?
  • 10.5. Are Humanitarian Efforts Being Directed Towards Fighting The 2014 Ebola Outbreak Having The Desired Effects?
  • 10.6. How Different Will The Socio-Political Landscape Of An Ebola-Free West Africa Be?

List of Tables

  • Table 1.1: EVD Incidence and Mortality In Guinea, Liberia, and Sierra Leone, 2014
  • Table 2.1: Ebola Genes and the Structural Proteins They Encode, 2014
  • Table 2.2: Selected Historical Outbreaks Of Ebola Disease: Year, Location, Number of Cases, and Fatality, 1976-2014
  • Table 3.1: Incidence Of Ebola In Europe and the US, 2014
  • Table 3.2: Ebola Incidence and Mortality in West Africa, 2014
  • Table 3.3: Countries Most Affected By Ebola And Their Recent Socio-Political Issues, 2014
  • Table 3.4: Public Engagement Strategies Being Used To Combat The Spread Of The Ebola Virus, 2014
  • Table 4.1: Advantages and Disadvantages of Point of Care Diagnostics, 2014
  • Table 4.2: Ebola Diagnostics: Currently Used Measures and R&D Pipeline, 2014
  • Table 4.3: Advantages and Disadvantages of the Direct and Indirect ELISA Detection Formats, 2014
  • Table 4.4: qPCR Detection Methods, 2014
  • Table 5.1: Ebola Treatments: Currently Used Measures and R&D Drugs Pipeline, 2014
  • Table 5.2: Molecular Components of ZMapp: Components, Manufacturers and Description, 2014
  • Table 5.3: Serepta Therapeutic's Drug Pipeline Portfolio - Products, Development Phases and Indications, 2014
  • Table 6.1: Selected Vaccine Preventable Diseases: Associated Conditions, Incidence rates, and Mortality Rates, 2013
  • Table 6.2A: Types of Vaccines and Their Description, 2014
  • Table 6.2B: Types of Vaccines and Their Description, 2014 (Continued)
  • Table 6.3: Selected Adult Prophylactic Vaccine Products and Pipeline Developments: Products, Manufacturers and Indications, 2014
  • Table 6.4: Adult Prophylactic Vaccines: Market Drivers and Restraints, 2014
  • Table 6.5: Ebola Vaccines: R&D Pipeline, 2014
  • Table 6.6: NewLink Genetics Ebola Vaccines: Projected Production Capacity, 2015
  • Table 7.1: Categories Of Biological Agents Used in Warfare or Terror Attacks, 2014
  • Table 8.1: Available and Required Beds for Ebola Treatment Units in the three Worst Hit Countries, 2014
  • Table 8.2: Medical Response Sent To West Africa By Various Countries During The Ebola Crisis, 2014

List of Figures

  • Figure 1.1: EVD Incidence and Mortality In Guinea, Liberia, and Sierra Leone, 2014
  • Figure 1.2: The Ebola Report - Report Segmentation and Coverage, 2014
  • Figure 2.1: Diagrammatic Illusion Of The Structure Of The Ebola Virus, 2014
  • Figure 2.2: Cellular Replication Mechanism Used By Ebola Virus, 2014
  • Figure 2.3: Symptoms of Ebola Virus Disease, 2014
  • Figure 2.4: The Symptomatic Progression of Ebola Virus Disease, 2014
  • Figure 2.5: Kikwit: The Epicentre of the 1995 Ebola Outbreak In DR Congo
  • Figure 2.6: Diagrammatic Representation Of The Routes Of Ebola Transmission, 2014
  • Figure 3.1: Ebola Outbreak In West Africa: Outbreak Distribution Map, 2014
  • Figure 4.1: Formats of Enzyme Linked Immunosorbent Assay (ELISA), 2014
  • Figure 4.2: The Process of Reverse Transcription Polymerase Chain Reaction (RT-PCR), 2014
  • Figure 5.1: Structure of BCX4430
  • Figure 5.2: Structure of Active Brincidofivir
  • Figure 5.3: Structure of Favipiravir, 2014
  • Figure 5.4: Structure of Lamivudine, 2014
  • Figure 5.5: Diagrammatic Representation of Convalescent Serum, 2014
  • Figure 6.1: Global Mortality Due to Vaccine Preventable Diseases in Children Under Five, Breakdown by Disease (%), 2008
  • Figure 6.2: GSK's Experimental ChAd Ebola Vaccine, 2014
  • Figure 7.1: Effect of the SARS Outbreak On Hong Kong's Economy: GDP and HK Stock Exchange, 1998-2005
  • Figure 7.2: US Civilian Biodefence Budget: Allocation by Governmental Body ($bn), 2014

Companies Listed

  • Abbvie
  • Aeras
  • Bavarian Nordic
  • BioCryst Pharmaceuticals
  • Chimerix Inc
  • Corgenix Medical Corporation
  • Crucell NV (J&J)
  • Defyrus Inc
  • DynPort Vaccine Company
  • Emergent BioSolutions
  • Forbes
  • Fujifilm Holding Corp
  • GeoVax Labs
  • Icon Genetics
  • Inviragen
  • Johnson&Johnson
  • Kentucky BioProcessing
  • LeafBio
  • Mapp Pharmaceuticals
  • MediVector Inc
  • Merck
  • New Link Genetic Corporation
  • Okairos AG
  • Profectus BioSciences
  • Reynolds American
  • Rio Tinto
  • Sanofi Pasteur
  • Serepta Therapeutics
  • TD Vaccines
  • Tekmira Pharmaceuticals
  • Thermo Fisher Scientific
  • Toyoma Chemical
  • Vaccine Technologies
  • Vale
  • Viiv Healthcare

Organisations Mentioned In The Report

  • Brook Haven University
  • Centers for Disease Control [US]
  • European Medicines Agency (EMA)
  • Flowminder [Sweden]
  • Food and Drugs Administration (FDA) [US]
  • Institut Pasteur
  • Institute of Tropical Medicine [Belgium]
  • International Medical Corp
  • Lancaster University [UK]
  • Médecins Sans Frontières
  • National Institute for Health and Care Excellence (NICE) [UK]
  • National Library of Medicine [US]
  • Public Health Agency of Canada (PHAC)
  • Red Cross
  • Research Centre for Zoonosis Control [Japan]
  • South African Medical Institute
  • Swiss Institute of Bioinformatics
  • University of Oxford
  • US Patent & Trademark Office
  • Vaccine Research Center (NIH) [US]
  • Wellcome Trust
  • World Health Organisation (WHO)
Back to Top